+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Endometrial Cancer Treatment Market by Treatment, Grade, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5888365
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Endometrial Cancer Treatment Market grew from USD 8.42 billion in 2023 to USD 8.87 billion in 2024. It is expected to continue growing at a CAGR of 5.47%, reaching USD 12.23 billion by 2030.

Endometrial cancer treatment encompasses a range of therapeutic approaches targeting cancer that begins in the endometrium, the lining of the uterus. It primarily involves surgery, radiation therapy, hormonal therapy, and chemotherapy. It is essential due to its rising incidence, especially among postmenopausal women, driven by risk factors such as obesity, aging, and hormonal imbalances. Application involves personalized treatment plans considering the cancer stage, grade, and patient's overall health. End-users mainly include hospitals, specialty cancer clinics, and research institutions. Key growth influencers include an increasing female geriatric population, advancements in targeted therapies, and a rising incidence rate. The onset of more efficient diagnostic tools and personalized medicine represents potential opportunities. To capitalize, stakeholders should focus on expanding clinical trials for novel drugs and investing in R&D for targeted and immunotherapeutic treatments. However, market growth faces challenges like high cost of treatment, limited accessibility in developing regions, and side effects associated with current therapies. Additionally, regulatory hurdles and extended timelines for drug approvals can impede progress. Limitations also emerge from the poor prognosis associated with the disease's advanced stages, necessitating early detection innovations. Best areas for innovation include the development of minimally invasive surgical techniques, enhancement in radiation delivery systems, and breakthroughs in non-invasive diagnostic tools, such as liquid biopsies or advanced imaging technologies. Moreover, digital health solutions, such as AI-powered platforms, could accelerate personalized treatment plans and improve patient outcomes. Understanding the competitive landscape, which comprises both established pharmaceutical giants and agile biotechnology firms, is essential. The market, exhibiting a future-oriented trajectory, suggests a steady increase in R&D investments. Therefore, strategic partnerships and collaborations with academic institutions and technology companies could foster enhanced innovation and maintain competitive advantage. Overall, pursuing these avenues could lead to significant improvements in patient care and broaden the therapeutic landscape.

Understanding Market Dynamics in the Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevelance of type 1 and type 2 endometrial cancer worldwide
    • Government initiatives to expand endometrial cancer treatment adoption
    • Emergence of personalized and targeted uterine cancer therapy
  • Market Restraints
    • Limited reimbursement structure for endometrial treatment
  • Market Opportunities
    • Ongoing research activities to develop novel endometrial cancer treatments
    • Favorable government approvals for endometrial cancer drugs
  • Market Challenges
    • Regulatory hurdles and risk associated with certain treatment

Exploring Porter’s Five Forces for the Endometrial Cancer Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Endometrial Cancer Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Endometrial Cancer Treatment Market

External macro-environmental factors deeply influence the performance of the Endometrial Cancer Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometrial Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Context Therapeutics Inc., CooperSurgical Inc., Eisai Co., Ltd., Elekta AB, F. Hoffmann-La Roche AG, General Electric Company, GlaxoSmithKline PLC, Hologic Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Koninklijke Philips N.V., LiNA Medical ApS, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endometrial Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment
    • Chemotherapy
    • Immunotherapy
    • Radiation Therapy
  • Grade
    • Type I
    • Type II
  • End-User
    • Ambulatory Surgical Centers
    • Cancer Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevelance of type 1 and type 2 endometrial cancer worldwide
5.1.1.2. Government initiatives to expand endometrial cancer treatment adoption
5.1.1.3. Emergence of personalized and targeted uterine cancer therapy
5.1.2. Restraints
5.1.2.1. Limited reimbursement structure for endometrial treatment
5.1.3. Opportunities
5.1.3.1. Ongoing research activities to develop novel endometrial cancer treatments
5.1.3.2. Favorable government approvals for endometrial cancer drugs
5.1.4. Challenges
5.1.4.1. Regulatory hurdles and risk associated with certain treatment
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Endometrial Cancer Treatment Market, by Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation Therapy
7. Endometrial Cancer Treatment Market, by Grade
7.1. Introduction
7.2. Type I
7.3. Type II
8. Endometrial Cancer Treatment Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Cancer Centers
8.4. Hospitals & Clinics
9. Americas Endometrial Cancer Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Endometrial Cancer Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Endometrial Cancer Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ENDOMETRIAL CANCER TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 30. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 47. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 50. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 102. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 114. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 117. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Endometrial Cancer Treatment Market, which are profiled in this report, include:
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Context Therapeutics Inc.
  • CooperSurgical Inc.
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Koninklijke Philips N.V.
  • LiNA Medical ApS
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information